NCT00246389

Brief Summary

The purpose of this study is to evaluate the effectiveness and safety of cyclobenzaprine HCl 5 mg (muscle spasm medication) taken three times a day, alone or in combination with ibuprofen 400 mg or 800 mg (pain relief medication) taken three times a day, for the treatment of back or neck muscle pain with muscle spasm.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for phase_4 pain

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Completion

Last participant's last visit for all outcomes

July 1, 2004

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

October 28, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 31, 2005

Completed
Last Updated

February 18, 2011

Status Verified

February 1, 2011

First QC Date

October 28, 2005

Last Update Submit

February 17, 2011

Conditions

Keywords

muscle spasmcyclobenzaprine hydrochloride

Outcome Measures

Primary Outcomes (1)

  • Subject-rated global impression of change from baseline, after seven days of treatment

Secondary Outcomes (1)

  • Subject global impression of change after 3 days; Proportion of responders after 3 and 7 days, Change from baseline in subject-rated pain intensity, muscle spasm intensity, functional ability, and medication helpfulness after 3 and 7 days.

Interventions

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Experiencing neck or back pain for no more than 14 days
  • Physician rating of the muscle spasm of the neck or back region as mild, moderate or severe
  • Ability to discontinue all muscle relaxants, NSAIDs (anti-inflammatory drugs) and pain relievers, other than the study medications during the 7-day treatment period. (Cardioprotective doses of aspirin (\<= 325 mg / day) may be taken.)

You may not qualify if:

  • History of physician-diagnosed musculoskeletal neck or back muscle spasms within 12 months prior to the study
  • neck or back pain radiating into the arms or legs
  • history of serious medical conditions
  • taken a narcotic or muscle relaxant within 12 hours of the baseline physician visit
  • allergies to aspirin, NSAIDs or cyclobenzaprine HCl.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Childers MK, Borenstein D, Brown RL, Gershon S, Hale ME, Petri M, Wan GJ, Laudadio C, Harrison DD. Low-dose cyclobenzaprine versus combination therapy with ibuprofen for acute neck or back pain with muscle spasm: a randomized trial. Curr Med Res Opin. 2005 Sep;21(9):1485-93. doi: 10.1185/030079905X61938.

MeSH Terms

Conditions

PainSpasm

Interventions

cyclobenzaprine

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeuromuscular ManifestationsNervous System Diseases

Study Officials

  • McNeil Consumer & Specialty Pharmaceuticals, a Division of Mc Neil-PPC, Inc. Clinical Trial

    McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 28, 2005

First Posted

October 31, 2005

Study Completion

July 1, 2004

Last Updated

February 18, 2011

Record last verified: 2011-02